SRT-3025

SRT-3025 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. It has been investigated as a potential treatment for osteoporosis,[1][2][3][4][5] and anemia.[6][7]

SRT-3025
Identifiers
  • 5-(3-methoxypropyl)-2-phenyl-N-[2-[6-(pyrrolidin-1-ylmethyl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]-1,3-thiazole-4-carboxamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC31H31N5O2S2
Molar mass569.74 g·mol−1
3D model (JSmol)
  • COCCCC1=C(N=C(S1)C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C4=NC5=C(S4)N=CC(=C5)CN6CCCC6
  • InChI=1S/C31H31N5O2S2/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37)
  • Key:MRRXPMZNBRXCPZ-UHFFFAOYSA-N

See also

References
  1. Li Y, Shen G, Yu C, Li G, Shen J, Gong J, Xu Y (December 2014). "Angiotensin II induces mitochondrial oxidative stress and mtDNA damage in osteoblasts by inhibiting SIRT1–FoxO3a–MnSOD pathway". Biochemical and Biophysical Research Communications. 455 (1–2): 113–8. doi:10.1016/j.bbrc.2014.10.123. PMID 25450701.
  2. Gurt I, Artsi H, Cohen-Kfir E, Hamdani G, Ben-Shalom G, Feinstein B, et al. (2015). "The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells". PLOS ONE. 10 (7): e0134391. Bibcode:2015PLoSO..1034391G. doi:10.1371/journal.pone.0134391. PMC 4520518. PMID 26226624.
  3. Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, et al. (October 2015). "Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs". Molecular Endocrinology. 29 (10): 1498–509. doi:10.1210/me.2015-1133. PMC 4588729. PMID 26287518.
  4. Zainabadi K (May 2019). "Drugs targeting SIRT1, a new generation of therapeutics for osteoporosis and other bone related disorders?". Pharmacological Research. 143: 97–105. doi:10.1016/j.phrs.2019.03.007. PMID 30862606.
  5. Artsi H, Gurt I, El-Haj M, Müller R, Kuhn GA, Ben Shalom G, et al. (2019). "Sirt1 Promotes a Thermogenic Gene Program in Bone Marrow Adipocytes: From Mice to (Wo)Men". Frontiers in Endocrinology. 10: 126. doi:10.3389/fendo.2019.00126. PMC 6403178. PMID 30873124.
  6. Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M (July 2015). "The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice". Stem Cell Research. 15 (1): 130–40. doi:10.1016/j.scr.2015.05.007. PMC 4516677. PMID 26046330.
  7. Lin X, Liu C, Wang T, Wang H, Shao Z (2019). "Sirt1 in the Regulation of Interferon Gamma in Severe Aplastic Anemia". Acta Haematologica. 142 (3): 142–148. doi:10.1159/000497404. PMID 31141802. S2CID 169038775.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.